Researchers and clinicians face ethical and policy-based challenges in disclosing, preventing and treating psychosis. Which diagnostic labels should be considered to motivate more effective public and professional dialogue about psychosis risk?
AMA J Ethics. 2016;18(6):624-632. doi:
10.1001/journalofethics.2016.18.6.msoc1-1606.
Some commentators say comparative trials of FDA-approved drugs are overburdened by current Common Rule regulations and that researchers should not be required to obtain explicit consent for participation in the most innocuous of these trials.
Instead of succumbing to the urge to portray cultural differences as a dichotomy between clashing opposites, we should endeavor to note our common humanity, acknowledge the plurality of viewpoints within a given culture, and appreciate that cultures can evolve without being untrue to themselves.